Wacker Signs Licensing Deal with Xoma

Wacker Biotech (Jena, Germany), a subsidiary of Wacker Chemie, says it has signed a licensing agreement with biopharmaceutical company Xoma (Berkeley, CA), to use Xoma’s bacterial cell expression technology for R&D. The agreement allows Wacker Biotech to combine its proprietary E. coli secretion technology with Xoma’s bacterial cell expression technology to produce antibodies and antibody fragments, Wacker Biotech says. Xoma will use Wacker Biotech’s E. coli secretion technology for a development project to produce an antibody fragment...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers